Evidence map›Paper›PMID 39128948›Full record

ArticleInternational journal of cancer2024

Cancer risk among people living with Human Immunodeficiency Virus (HIV) in Rwanda from 2007 to 2018.

Jean Claude Dusingize, Gad Murenzi, Benjamin Muhoza, Lydia Businge, Eric Remera, Francois Uwinkindi, Marc Hagenimana, Gallican Rwibasira, Sabin Nsanzimana, Philip E Castle and 2 more

Abstract read
In one paragraph

Article in International journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jean Claude DusingizeCancer Epidemiology, Prevention & Control Program, Montefiore Einstein Cancer Center, Bronx, New York, USA.ORCID 0000-0001-5721-100X
Gad MurenziEinstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.
Benjamin MuhozaEinstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.
Lydia BusingeRwanda Biomedical Centre, Kigali, Rwanda.
Eric RemeraRwanda Biomedical Centre, Kigali, Rwanda.
Francois UwinkindiRwanda Biomedical Centre, Kigali, Rwanda.
Marc HagenimanaRwanda Biomedical Centre, Kigali, Rwanda.
Gallican RwibasiraRwanda Biomedical Centre, Kigali, Rwanda.
Sabin NsanzimanaThe Ministry of Health of Rwanda, Kigali, Rwanda.
Philip E CastleDivisions of Cancer Prevention and Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Kathryn AnastosDepartment of Medicine and of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Gary M CliffordEarly Detection Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-7534-333X

Funding

"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
Einstein/Rwanda/DRC Consortium for Research in HIV/HPV/MalignanciesU54CA254568 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI YOTEBIENG, MARCEL · 2020 to 2024
$5.1M
Shared ResourcesU54CA190163 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ANASTOS, KATHRYN M., CASTLE, PHILIP E · 2014 to 2019
$4.1M
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research CenterP20CA210284 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CASTLE, PHILIP E · 2017 to 2018
$589k
Bill and Melinda Gates Foundation INV-007104 / OPP1053353Gates Foundation INV-007104National Institutes of Health (NIH) P20CA210284National Institutes of Health (NIH) U54CA254568NCI NIH HHS P20 CA210284NCI NIH HHS U54 CA190163NCI NIH HHS U54 CA254568NIAID NIH HHS U01 AI096299World Health Organization 001
6 · The paper itself

Abstract

Assessing the risk of cancer among people living with HIV (PLHIV) in the current era of antiretroviral therapy (ART) is crucial, given their increased susceptibility to many types of cancer and prolonged survival due to ART exposure. Our study aims to compare the association between HIV infection and specific cancer sites in Rwanda. Population-based cancer registry data were used to identify cancer cases in both PLHIV and HIV-negative persons. A probabilistic record linkage approach between the HIV and cancer registries was used to supplement HIV status ascertainment in the cancer registry. Associations between HIV infection and different cancer types were evaluated using unconditional logistic regression models. We performed several sensitivity analyses to assess the robustness of our findings and to evaluate the potential impact of different assumptions on our results. From 2007 to 2018, the cancer registry recorded 17,679 cases, of which 7% were diagnosed among PLHIV. We found significant associations between HIV infection and Kaposi's Sarcoma (KS) (adjusted odds ratio [OR]: 29.1, 95% CI: 23.2-36.6), non-Hodgkin lymphoma (NHL) (1.6, 1.3-2.0), Hodgkin lymphoma (HL) (1.6, 1.1-2.4), cervical (2.3, 2.0-2.7), vulvar (4.0, 2.5-6.5), penile (3.0, 2.0-4.5), and eye cancers (2.2, 1.6-3.0). Men living with HIV had a higher risk of anal cancer (3.1, 1.0-9.5) than men without HIV, but women living with HIV did not have higher risk than women without HIV (1.0, 0.2-4.3). Our study found that in an era of expanded ART coverage in Rwanda, HIV is associated with a broad range of cancers, particularly those linked to viral infections.

Indexed as

HIV InfectionsNeoplasmsRegistriesAdolescentAdultAgedFemaleHumansLymphoma, Non-HodgkinMaleMiddle AgedRisk FactorsRwandaSarcoma, KaposiYoung Adultcancerdata linkageepidemiologyHIV infection

Identifiers

PMID39128948
PMCPMC12173455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.